CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

GSK's ViiV reports higher adherence with injectable HIV treatment versus daily pills in US study

By Public Technologies
  • GSK’s majority-owned ViiV Healthcare will present findings linking Vocabria with Rekambys to better adherence than daily oral HIV therapy at HIV Glasgow.
  • The US real-world study also found patients receiving the injectable regimen were more likely to remain on treatment.
  • Pipeline findings support further evaluation of investigational HIV treatments VH184 and VH499 for potential twice-yearly dosing; neither is approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611091000BIZWIRE_USPR_____20261109_BW813778) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk